ClinicalTrials.gg
RecruitingNCT02617004GRAALL-2014/BUpdated Feb 19, 2019

Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults

An observational study in Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2019-02-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2020, 5 years 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Philadelphia Chromosome with a site in France — 2 open to participants now, 5 under way, 4 of them phase 3. Philadelphia Chromosome · France.

Started
2016
with 1 other
Observational
Only one
of the 14
Registered
9th of 14
by date
Lead sponsor
3 of 14
Assistance Publique - Hôpitaux de Paris

Among the 14 studies in Philadelphia Chromosome with a site in France, this one is one of 2 that started in 2016, is the only observational one, and was the 9th registered.

Philadelphia Chromosome

52 studies on the registry are indexed under Philadelphia Chromosome; 13 are open to participants now.

Browse Philadelphia Chromosome studies →

Open to participants now

2 of the 14 studies in Philadelphia Chromosome with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Philadelphia Chromosome studies recruiting now, 5 (50%) set no upper age limit and 5 (50%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Philadelphia Chromosome with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to prospectively validate the new risk model, based on minimal residual disease (MRD) response level and oncogenetic status by comparing historical results of GRAALL-2005 with those of GRAALL-2014 in an identical population of patients (Philadelphia chromosome negative, B lineage ALL, aged 18 to 59 years old).

03

Conditions studied

  • Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Young Adults (age 18-59) with Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Whose blood and bone marrow explorations have been completed before the prephase
  2. Aged 18 to 59 years old with not previously treated (including intrathecal injection) B-lineage-ALL newly diagnosed according to the WHO 2008 definition with ≥ 20% bone marrow blasts
  3. Whose karyotype shows no t(9;22) and/or the absence in molecular biology of breakpoint cluster region-Abelson (BCR-ABL)
  4. With (ECOG) performance status ≤3
  5. With or without central nervous system (CNS) or testis involvement
  6. Without other evolving cancer (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix) or its radiotherapy or chemotherapy treatment should be finished at least since 6 months
  7. Having signed a written
  8. With efficient for women of childbearing age (excluding estrogens and IUD)
  9. With health insurance coverage
  10. Who have received or being receiving the steroid prephase

Exclusion criteria

Exclusion Criteria:

  1. With lymphoblastic lymphoma and bone marrow blasts \< 20%, Burkitt-type ALL, or with antecedents of chronic myeloid leukemia (CML) or other myeloproliferative neoplasm
  2. With to anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the ALL:

    • (AST) and/or alanine transaminase (ALT) > 5 x (ULN)
    • Total ≥ 2.5 x upper limit of normal range (ULN)
    • Creatinine >1.5x upper limit of normal range (ULN) or \<50 mL/mn
  3. Myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy ( grade III or IV), left ventricle (LVEF) \< 50% and or Shortening fraction \< 30%,
  4. Active severe infection or known seropositivity for or human T cell leukemia/lymphoma virus type 1 (HTLV1) or active or C
  5. Pregnant (beta-Human Chorionic Gonadotropin positive) or nursing woman
  6. Not able to bear with the procedures or the frequency of visits planned in the trial
  7. Unable to consent, under tutelage or curators, or judiciary safeguard.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Disease free survival (DFS)

    Time frame: 4 years

Secondary outcomes

  1. Cumulative incidence of relapse (CIR)

    Time frame: 4 years

  2. non relapse mortality (NMR)

    Time frame: 4 years

  3. Overall survival

    Time frame: 4 years

  4. Cumulative incidence of relapse (CIR) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)

    Time frame: 4 years

  5. overall survival after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)

    Time frame: 4 years

  6. Non relapse mortality (NRM) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)

    Time frame: 4 years

  7. Disease free survival (DFS) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)

    Time frame: 4 years

  8. Minimal residual disease (MRD)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Hématologie Adulte, Saint Louis hospital
    Paris, 75010, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Dec 2020 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Nov 30, 2015
Start
Feb 2016
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2025
Last update
Feb 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02617004
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Feb 2016
Primary completion
Dec 2020 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 19, 2019

Study contacts

Hervé Dombret, MDPhD
Contact
herve.dombret@aphp.fr
+33 (0)1 57 27 68 47
Véronique Lhéritier
Contact
veronique.lheritier@chu-lyon.fr
+33(0)4 78 86 22 39
Hervé Dombret, MDPhD
principal investigator · APHP

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion